CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
急性髓系白血病常规免疫治疗与纳米免疫治疗综述
英文原题：A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia.
查看英文原题
A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
急性髓系白血病（AML）是一种高度侵袭性的血液系统恶性肿瘤。传统化疗不仅会造成严重副作用，还会使部分患者出现高复发率和耐药。然而，作为一种新兴治疗策略，免疫治疗近年来在 AML 治疗领域显示出巨大潜力。目前 AML 的常见免疫疗法包括单克隆抗体、CAR-T 细胞疗法和免疫检查点抑制剂。随着研究深入和技术进步，尤其是纳米技术在医学中的应用，新型免疫疗法有望在未来成为治疗 AML 的重要手段之一。
展开英文摘要原文
Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy. Traditional chemotherapy methods not only bring serious side effects, but also lead to high recurrence rate and drug resistance in some patients.
However, as an emerging therapeutic strategy, immunotherapy has shown great potential in the field of AML treatment in recent years. At present, common immunotherapy methods for AML include monoclonal antibodies, CAR-T cell therapy, and immune checkpoint inhibitors. With the deepening of research and technological progress, especially the application of nanotechnology in medicine, new immunotherapy is expected to become one of the important means for the treatment of acute myeloid leukemia in the future.
论文信息
- 作者
- Wang Y、Yang X、Liu Y、Li Y
- 第一作者单位
- Department of Pediatrics of Yantai Affiliated Hospital, The Second Clinical Medical College of Binzhou Medical University, Yantai, Shandong, China.China
- 通讯作者单位
- Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, Shandong, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40129984 · DOI 10.3389/fimmu.2025.1505247
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →